499 results on '"Paulsen, Frank"'
Search Results
152. Kinetic analysis of dynamic 18F-fluoromisonidazole PET correlates with radiation treatment outcome in head-and-neck cancer
- Author
-
Thorwarth, Daniela, primary, Eschmann, Susanne-Martina, additional, Scheiderbauer, Jutta, additional, Paulsen, Frank, additional, and Alber, Markus, additional
- Published
- 2005
- Full Text
- View/download PDF
153. Intensity modulated radiotherapy for high risk prostate cancer based on sentinel node SPECT imaging for target volume definition
- Author
-
Ganswindt, Ute, primary, Paulsen, Frank, additional, Corvin, Stefan, additional, Eichhorn, Kai, additional, Glocker, Stefan, additional, Hundt, Ilse, additional, Birkner, Mattias, additional, Alber, Markus, additional, Anastasiadis, Aristotelis, additional, Stenzl, Arnulf, additional, Bares, Roland, additional, Budach, Wilfried, additional, Bamberg, Michael, additional, and Belka, Claus, additional
- Published
- 2005
- Full Text
- View/download PDF
154. A kinetic model for dynamic [18F]-Fmiso PET data to analyse tumour hypoxia
- Author
-
Thorwarth, Daniela, primary, Eschmann, Susanne M, additional, Paulsen, Frank, additional, and Alber, Markus, additional
- Published
- 2005
- Full Text
- View/download PDF
155. The benefit of functional???anatomical imaging with [18F]fluorodeoxyglucose utilizing a dual-head coincidence gamma camera with an integrated X-ray transmission system in non-small cell lung cancer
- Author
-
Eschmann, Susanne M., primary, Bitzer, Michael, additional, Paulsen, Frank, additional, Friedel, Godehard, additional, Besenfelder, Hariolf, additional, Horger, Marius, additional, Reimold, Matthias, additional, Dittmann, Helmut, additional, Pfannenberg, Anna C., additional, and Bares, Roland, additional
- Published
- 2004
- Full Text
- View/download PDF
156. [ 18 F]FLT PET for diagnosis and staging of thoracic tumours
- Author
-
Dittmann, Helmut, primary, Dohmen, Bernhard Matthias, additional, Paulsen, Frank, additional, Eichhorn, Kai, additional, Eschmann, Susanne Martina, additional, Horger, Marius, additional, Wehrmann, Manfred, additional, Machulla, Hans Juergen, additional, and Bares, Roland, additional
- Published
- 2003
- Full Text
- View/download PDF
157. Strahlentherapie des Melanoms.
- Author
-
Garbe, Claus, Kortmann, Rolf-Dieter, Hehr, Thomas, Claßen, Johannes, Paulsen, Frank, and Bamberg, Michael
- Published
- 2006
- Full Text
- View/download PDF
158. Radiosurgery for brain metastases: the Tuebingen experience
- Author
-
Becker, Gerd, primary, Jeremic, Branislav, additional, Engel, Corinna, additional, Buchgeister, Markus, additional, Paulsen, Frank, additional, Duffner, Frank, additional, Meisner, Christoph, additional, and Bamberg, Michael, additional
- Published
- 2002
- Full Text
- View/download PDF
159. Evaluation of predictive factors for local tumour control after electron-beam-rotation irradiation of the chest wall in locally advanced breast cancer
- Author
-
Hehr, Thomas, primary, Budach, Wilfried, additional, Paulsen, Frank, additional, Gromoll, Christian, additional, Christ, Gunther, additional, and Bamberg, Michael, additional
- Published
- 1999
- Full Text
- View/download PDF
160. Hypoxia-imaging with 18F-Misonidazole and PET: Changes of kinetics during radiotherapy of head-and-neck cancer
- Author
-
Eschmann, Susanne Martina, Paulsen, Frank, Bedeshem, Claudia, Machulla, Hans-Jürgen, Hehr, Thomas, Bamberg, Michael, and Bares, Roland
- Subjects
- *
TUMORS , *RADIOTHERAPY , *HYPOXEMIA , *HEAD & neck cancer - Abstract
Abstract: Background and purpose: PET with 18F-Misonidazole (FMISO-PET) is a non-invasive method for measuring tumor hypoxia. We analysed changes of FMISO-uptake during radiotherapy and their impact on patient outcome. Materials and methods: Fourteen patients with HNC underwent repeated FMISO-PET prior to radiotherapy and after 30Gy. Dynamic and static PET-scans (2+4h p.i.) were acquired. FMISO-uptake was quantified by calculating standard uptake values (SUV) and tumor-muscle-ratios (TMR). Kinetic curve types representing tissue hypoxia were defined. Change of curve type was correlated with patient outcome. Results: The mean SUV 4h p.i. and the TMR decreased significantly during radiotherapy. SUV decreased clearly in 12/14 patients, and increased in 2 patients. TMR decreased in 11 patients, and increased in 3 patients. Prior to radiotherapy, three different shapes of kinetic curve types indicative for the degree of hypoxia could be defined in 12/14 patients: (1) accumulation type (severe hypoxia (n =8)), (2) intermediate type (intermediate degree of hypoxia (n =3)), and (3) wash-out type (low degree of hypoxia (n =1)). Curve type changed towards a lower degree of hypoxia at 30Gy in all but 3 patients. In three patients curve type remained unchanged. Conclusions: The changes in tumor FMISO-uptake during radiotherapy indicate radio-induced reoxygenation. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
161. 18F-FDG PET for assessment of therapy response and preoperative re-evaluation after neoadjuvant radio-chemotherapy in stage III non-small cell lung cancer.
- Author
-
Eschmann, Susanne Martina, Friedel, Godehard, Paulsen, Frank, Reimold, Matthias, Hehr, Thomas, Budach, Wilfried, Langen, Heinz-Jakob, and Bares, Roland
- Subjects
LUNG cancer ,DRUG therapy ,MEDIASTINOSCOPY ,POSITRON emission tomography ,LYMPH nodes ,METASTASIS - Abstract
The aim of this study was to evaluate FDG-PET for assessment of therapy response and for prediction of patient outcome after neo-adjuvant radio-chemotherapy (NARCT) of advanced non-small cell lung cancer (NSCLC). Seventy patients with histologically proven stage III NSCLC underwent FDG-PET investigations before and after NARCT. Changes in FDG uptake and PET findings after completion of NARCT were compared with (1) the histology of tumour samples obtained at surgery or repeat mediastinoscopy, and (2) treatment results in terms of achieved operability and long-term survival. The mean average FDG uptake of the primary tumours in the patient group decreased significantly during NARCT ( p = 0.004). Sensitivity, specificity and overall accuracy of FDG-PET were 94.5%, 80% and 91%, respectively, for the detection of residual viable primary tumour, and 77%, 68% and 73%, respectively, for the presence of lymph node metastases. A negative PET scan or a reduction in the standardised uptake value (SUV) of more than 80% was the best predictive factor for a favourable outcome of further treatment. Progressive disease according to PET (new tumour manifestations or increasing SUV) was significantly correlated with an unfavourable outcome ( p = 0.005). In this subgroup, survival of patients who underwent surgery was not significantly different from survival among those who did not undergo surgery, whereas for the whole patient group, complete tumour resection had a significant influence on outcome. FDG-PET is suitable to assess response to NARCT in patients with stage III NSCLC accurately. It was highly predictive for treatment outcome and patient survival. PET may be helpful in improving restaging after NARCT by allowing reliable assessment of residual tumour viability. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
162. Prognostic Impact of Hypoxia Imaging with 18F-Misonidazole PET in Non-Small Cell Lung Cancer and Head and Neck Cancer Before Radiotherapy.
- Author
-
Eschmann, Susanne-Martina, Paulsen, Frank, Reimold, Matthias, Dittmann, Helmut, Welz, Stefan, Reischl, Gerald, Machulla, Hans-Juergen, and Bares, Roland
- Published
- 2005
163. The benefit of functional-anatomical imaging with [18F]fluorodeoxyglucose utilizing a dual-head coincidence gamma camera with an integrated X-ray transmission system in non-small cell lung cancer.
- Author
-
Eschmann, Susanne M., Bitzer, Michael, Paulsen, Frank, Friedel, Godehard, Besenfelder, Hariolf, Horger, Marius, Reimold, Matthias, Dittmann, Helmut, Pfannenberg, Anna C., and Bares, Roland
- Published
- 2004
- Full Text
- View/download PDF
164. [[sup18] F ]FLT PET for diagnosis and staging of thoracic tumours.
- Author
-
Dittmann, Helmut, Dohmen, Bernhard Matthias, Paulsen, Frank, Eichhorn, Kai, Eschmann, Susanne Martina, Horger, Marius, Wehrmann, Manfred, Machulla, Hans Juergen, and Bares, Roland
- Subjects
POSITRON emission tomography ,CANCER patients ,NUCLEOSIDES - Abstract
The nucleoside analogue 37prime;-deoxy-37prime;-[18F]-fluorothymidine (FLT) has been introduced for imaging of tumour cell proliferation by positron emission tomography (PET). This study evaluated the use of FLT in patients with thoracic tumours prior to treatment. Whole-body FLT PET was performed in 16 patients with 18 tumours [17 thoracic tumours (nine non-small cell lung cancers, five oesophageal carcinomas, two sarcomas, one Hodgkin’s lymphoma) and one renal carcinoma] before treatment. Fluorine-18 fluorodeoxyglucose (FDG) PET was performed for comparison except in those patients with oesophageal carcinoma. For semi-quantitative analysis, the average and maximum standardised uptake values (avgSUV and maxSUV, respectively) (FLT, 114±20 min p.i.; FDG, 87±8 min p.i.; 50% isocontour region of interest) was calculated. All 17 thoracic tumours and 19/20 metastases revealed significant FLT accumulation, resulting in easy delineation from surrounding tissue. The additional small grade 1 renal carcinoma was not detected with either FLT or FDG. In most lung tumours (avgSUV 1.5–8.2) and metastases, FLT showed intense uptake. However, one of two spinal bone metastases was missed owing to the high physiological FLT uptake in the surrounding bone marrow. Oesophageal carcinoma primaries (avgSUV 2.7–10.0) and occasional metastases showed particularly favourable tumour/non-tumour contrast. Compared with FDG, tumour uptake of FLT was lower (avgSUV, P=0.0006; maxSUV, P=0.0001), with a significant linear correlation (avgSUV, r²=0.45; maxSUV, r²=0.49) between FLT and FDG. It is concluded that FLT PET accurately visualises thoracic tumour lesions. In the liver and the bone marrow, high physiological FLT uptake hampers detection of metastases. On the other hand, FLT may be favourable for imaging of brain metastases owing to the low physiological uptake. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
165. Appendicitis during locoregional thermoradiotherapy of advanced or recurrent rectal and cervical cancer, a report of two cases.
- Author
-
Hehr, Thomas, Budach, Wilfried, Lamprecht, Ulf, Paulsen, Frank, Gromoll, Christian, and Bamberg, Michael
- Subjects
CANCER radiotherapy complications ,APPENDICITIS ,FEVER therapy - Abstract
Introduction : Local tumour control after irradiation alone for advanced, inoperable carcinomas of the bladder and rectum or inoperable recurrent cervical carcinoma is usually disappointing. Both preclinical and clinical studies reported improvements by adding hyperthermia to radiotherapy. Reports for phase II/ III trials do not indicate any enhanced side effects. However, two cases of acute suppurating appendicitis were observed in a series of patients treated with deep regional hyperthermia. Materials, methods and results : Eighty patients with advanced, inoperable, or recurrent rectal or recurrent cervical tumours were treated with deep regional hyperthermia (313 sessions) in addition to radiotherapy between September 1995 and October 1998. The treatment for two of these patients (2.5%) had to be discontinued after the fourth/second hyperthermia treatments at 19.8/10.8Gy total dose, respectively, for symptoms of pain in the right pelvis and elevated rectal temperature. Both patients underwent laparotomy and were found to have suppurative appendicitis. In addition to the retrocoecal location in both patients, evidence of preexisting chronic appendicitis, and appendiceal faecalith were observed in each patient. Conclusion : The development of acute appendicitis in 2.5% of patients during a course of deep regional thermoradiotherapy for pelvic tumour is much higher than the expected incidence of appendicitis in the general population (< 10/00) (Korner et al. 1997). An enhanced risk of suppurative appendicitis in patients undergoing pelvic thermoradiotherapy cannot be excluded, especially in retrocoecal located appendices with obstructed appendix lumen from preexisting chronic appendicitis or faecalith. [ABSTRACT FROM AUTHOR]
- Published
- 1999
- Full Text
- View/download PDF
166. Limiter Intermodulation Improvement Due to Selective Carrier Spacing.
- Author
-
Johannsen, Klaus and Paulsen, Frank
- Published
- 1976
- Full Text
- View/download PDF
167. Television Sound Subcarrier Transmission in Space Communication.
- Author
-
Johannsen, Klaus, Paulsen, Frank, and Morton, John
- Published
- 1974
- Full Text
- View/download PDF
168. First Experience and Prospective Evaluation on Feasibility and Acute Toxicity of Online Adaptive Radiotherapy of the Prostate Bed as Salvage Treatment in Patients with Biochemically Recurrent Prostate Cancer on a 1.5T MR-Linac.
- Author
-
Wegener, Daniel, Thome, Alexandra, Paulsen, Frank, Gani, Cihan, Boldt, Jessica, Butzer, Sarah, Thorwarth, Daniela, Moennich, David, Nachbar, Marcel, Müller, Arndt-Christian, Zips, Daniel, and Boeke, Simon
- Subjects
- *
PROSTATE cancer , *PROSTATE cancer patients , *RADICAL prostatectomy , *MAGNETIC resonance imaging , *PROSTATE , *RADIOTHERAPY - Abstract
Introduction: Novel MRI-linear accelerator hybrids (MR-Linacs, MRL) promise an optimization of radiotherapy (RT) through daily MRI imaging with enhanced soft tissue contrast and plan adaptation on the anatomy of the day. These features might potentially improve salvage RT of prostate cancer (SRT), where the clinical target volume is confined by the mobile organs at risk (OAR) rectum and bladder. So far, no data exist about the feasibility of the MRL technology for SRT. In this study, we prospectively examined patients treated with SRT on a 1.5 T MRL and report on workflow, feasibility and acute toxicity. Patients and Methods: Sixteen patients were prospectively enrolled within the MRL-01 study (NCT: NCT04172753). All patients were staged and had an indication for SRT after radical prostatectomy according to national guidelines. RT consisted of 66 Gy in 33 fractions or 66.5/70 Gy in 35 fractions in case of a defined high-risk region. On the 1.5 T MRL, daily plan adaption was performed using one of two workflows: adapt to shape (ATS, using contour adaptation and replanning) or adapt to position (ATP, rigid replanning onto the online anatomy with virtual couch shift). Duration of treatment steps, choice of workflow and treatment failure were recorded for each fraction of each patient. Patient-reported questionnaires about patient comfort were evaluated as well as extensive reporting of acute toxicity (patient reported and clinician scored). Results: A total of 524/554 (94.6%) of fractions were successfully treated on the MRL. No patient-sided treatment failures occurred. In total, ATP was chosen in 45.7% and ATS in 54.3% of fractions. In eight cases, ATP was performed on top of the initial ATS workflow. Mean (range) duration of all fractions (on-table time until end of treatment) was 25.1 (17.6–44.8) minutes. Mean duration of the ATP workflow was 20.60 (17.6–25.2) minutes and of the ATS workflow 31.3 (28.2–34.1) minutes. Patient-reported treatment experience questionnaires revealed high rates of tolerability of the treatment procedure. Acute toxicity (RTOG, CTC as well as patient-reported CTC, IPSS and ICIQ) during RT and 3 months after was mild to moderate with a tendency of recovery to baseline levels at 3 months post RT. No G3+ toxicity was scored for any item. Conclusions: In this first report on SRT of prostate cancer patients on a 1.5 T MRL, we could demonstrate the feasibility of both available workflows. Daily MR-guided adaptive SRT of mean 25.1 min per fraction was well tolerated in this pretreated collective, and we report low rates of acute toxicity for this treatment. This study suggests that SRT on a 1.5 T MRL can be performed in clinical routine and it serves as a benchmark for future analyses. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
169. A kinetic model for dynamic [<SUP>18</SUP>F]-Fmiso PET data to analyse tumour hypoxia
- Author
-
Thorwarth, Daniela, Eschmann, Susanne M, Paulsen, Frank, and Alber, Markus
- Abstract
A method is presented to identify and quantify hypoxia in human head-and-neck tumours based on dynamic [18F]-Fmiso PET patient data, using a model for the tracer transport. A compartmental model was developed, inspired by recent immunohistochemical investigations with the tracer pimonidazole. In order to take the trapping of the tracer and the diffusion in interstitial space into account, the kinetic model consists of two compartments and a specific input function. This voxel-based data analysis allows us to decompose the time-activity curves (TACs) into their perfusion, diffusion and hypoxia-induced retention components. This characterization ranges from well perfused tumours over diffusion limited hypoxia to strong hypoxia and necrosis. The overall shape of the TAC and the model parameters may point at the structural architecture of the tissue sample. The model addresses the two main problems associated with hypoxia imaging with PET. Firstly, the hypoxic areas are spatially separated from well perfused vessels, causing long diffusion times of the tracer. Secondly, tracer uptake occurs only in viable hypoxic cells, which constitute only a small subpopulation in the presence of necrosis. The resulting parameters such as the concentration of hypoxic cells and the perfusion are displayed in parameter plots (hypoxia map). Quantification of hypoxia performed with the presented kinetic model is more reliable than a criterion based on static standardized uptake values (SUV) at an early timepoint, because severely hypoxic/necrotic tissues show low uptake and are thus overlooked by SUV threshold identification. The derived independent measures for perfusion and hypoxia may provide a basis for individually adapted treatment planning.
- Published
- 2005
170. Correction to: Retrospective analysis of fractionated intensity-modulated radiotherapy (IMRT) in the interdisciplinary management of primary optic nerve sheath meningiomas.
- Author
-
Eckert, Franziska, Clasen, Kerstin, Kelbsch, Carina, Tonagel, Felix, Bender, Benjamin, Tabatabai, Ghazaleh, Zips, Daniel, Thorwarth, Daniela, Frey, Bettina, Becker, Gerd, Wilhelm, Helmut, and Paulsen, Frank
- Subjects
OPTIC nerve ,INTENSITY modulated radiotherapy ,RETROSPECTIVE studies - Abstract
An amendment to this paper has been published and can be accessed via the original article. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
171. A multi-institutional series of a novel, recurrent TRIM24::MET fusion-driven infant-type hemispheric glioma reveals significant clinico-pathological heterogeneity.
- Author
-
Gorodezki, David, Chiang, Jason, Viaene, Angela N., Sievers, Philipp, Schmid, Simone, Holzer, Ursula, Paulsen, Frank, Schuhmann, Martin U., Witt, Olaf, Schittenhelm, Jens, and Ebinger, Martin
- Subjects
- *
INFRATENTORIAL brain tumors , *GLIOMAS , *PROTEIN-tyrosine kinase inhibitors , *CEREBRAL hemispheres , *BREAST ,CENTRAL nervous system tumors - Abstract
Within the past decade, incremental integration of molecular characteristics into the classification of central nervous system neoplasms increasingly facilitated precise diagnosis and advanced stratification, beyond potentially providing the foundation for advanced targeted therapies. We report a series of three cases of infant-type hemispheric glioma (IHG) involving three infants diagnosed with neuroepithelial tumors of the cerebral hemispheres harboring a novel, recurrent TRIM24::MET fusion. Histopathology showed glial tumors with either low-grade or high-grade characteristics, while molecular characterization found an additional homozygous CDKN2A/B deletion in two cases. Two patients showed leptomeningeal dissemination, while multiple supra- and infratentorial tumor manifestations were found in one case. Following subtotal resection (two cases) and biopsy (one case), treatment intensity of adjuvant chemotherapy regimens did not reflect in the progression patterns within the reported cases. Two patients showed progression after first-line treatment, of which one patient died not responding to tyrosine kinase inhibitor cabozantinib. As the detection of a recurrent TRIM24::MET fusion expands the spectrum of renowned driving fusion genes in IHG, this comparative illustration may indicate a distinct clinico-pathological heterogeneity of tumors bearing this driver alteration. Upfront clinical trials of IHG promoting further characterization and the implementation of individualized therapies involving receptor tyrosine kinase inhibition are required. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
172. App-based assessment of patient-reported outcomes in the Molecular Tumor Board in the Center for Personalized Medicine—(TRACE).
- Author
-
Dörner, Lorenz, Grosse, Lucia, Stange, Felix, Hille, Hanni, Kurz, Sylvia, Becker, Hannes, Volkmer, Sebastian, Hippler, Melina, Rieger, David, Bombach, Paula, Rieger, Johannes, Weinert, Lina, Svensson, Laura, Anders, Carolin, Cekin, Sila, Paulsen, Frank, Öner, Öznur, Ruhm, Kristina, Malek, Holly Sundberg, and Möller, Yonne
- Subjects
- *
PATIENT reported outcome measures , *PATIENTS' attitudes , *MEDICAL personnel , *QUALITY of life , *INDIVIDUALIZED medicine - Abstract
Background Biomarker-based therapies are increasingly used in cancer patients outside clinical trials. Systematic assessment of patient-reported outcomes (PRO) is warranted to take patients' perspectives during biomarker-based therapies into consideration. We assessed the feasibility of an electronic PRO assessment via a smartphone application. Methods An interdisciplinary expert panel developed a smartphone application based on symptom burden and health-related quality of life (HRQoL) metrics reported in a retrospective analysis of 292 neuro-oncological patients. The app included validated assessments of health-related quality of life (HRQoL), the burden of symptoms, and psychological stress. Feasibility and usability were tested in a pilot study. Semi-structured interviews with patients and health care professionals (HCP) were conducted, transcribed, and analyzed according to Mayring´s qualitative content analysis. Furthermore, we assessed compliance and descriptive data of ePROs. Results A total of 14 patients have been enrolled, (9 female, 5 male). A total of 4 HCPs, 9 patients, and 1 caregiver were interviewed regarding usability/feasibility. The main advantages were the possibility to complete questionnaires at home and comfortable implementation in daily life. Compliance was high, for example, 82% of the weekly distributed NCCN distress thermometer questionnaires were answered on time, however, with interindividual variability. We observed a median distress score of 5 (range 0–10, 197 results, n = 12, weekly assessed) and a median Global health score of 58.3 according to the EORTC QLQ-C30 instrument (range 16.7–100, 77 results, n = 12, monthly assessed). Conclusions This pilot study proved the feasibility and acceptance of the app. We will therefore expand its application during biomarker-guided therapies to enable systematic PRO assessments. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
173. Online Adaptive MR-Guided Ultrahypofractionated Radiotherapy of Prostate Cancer on a 1.5 T MR-Linac: Clinical Experience and Prospective Evaluation.
- Author
-
Potkrajcic, Vlatko, Gani, Cihan, Fischer, Stefan Georg, Boeke, Simon, Niyazi, Maximilian, Thorwarth, Daniela, Voigt, Otilia, Schneider, Moritz, Mönnich, David, Kübler, Sarah, Boldt, Jessica, Hoffmann, Elgin, Paulsen, Frank, Mueller, Arndt-Christian, and Wegener, Daniel
- Subjects
- *
CANCER radiotherapy , *RADIOTHERAPY , *PROSTATE cancer , *PROSTATE cancer patients , *TREATMENT failure , *TREATMENT duration - Abstract
The use of hypofractionated radiotherapy in prostate cancer has been increasingly evaluated, whereas accumulated evidence demonstrates comparable oncologic outcomes and toxicity rates compared to normofractionated radiotherapy. In this prospective study, we evaluate all patients with intermediate-risk prostate cancer treated with ultrahypofractionated (UHF) MRI-guided radiotherapy on a 1.5 T MR-Linac within our department and report on workflow and feasibility, as well as physician-recorded and patient-reported longitudinal toxicity. A total of 23 patients with intermediate-risk prostate cancer treated on the 1.5 T MR-Linac with a dose of 42.7 Gy in seven fractions (seven MV step-and-shoot IMRT) were evaluated within the MRL-01 study (NCT04172753). The duration of each treatment step, choice of workflow (adapt to shape-ATS or adapt to position-ATP) and technical and/or patient-sided treatment failure were recorded for each fraction and patient. Acute and late toxicity were scored according to RTOG and CTC V4.0, as well as the use of patient-reported questionnaires. The median follow-up was 12.4 months. All patients completed the planned treatment. The mean duration of a treatment session was 38.2 min. In total, 165 radiotherapy fractions were delivered. ATS was performed in 150 fractions, 5 fractions were delivered using ATP, and 10 fractions were delivered using both ATS and ATP workflows. Severe acute bother (G3+) regarding IPS-score was reported in five patients (23%) at the end of radiotherapy. However, this tended to normalize and no G3+ IPS-score was observed later at any point during follow-up. Furthermore, no other severe genitourinary (GU) or gastrointestinal (GI) acute or late toxicity was observed. One-year biochemical-free recurrence survival was 100%. We report the excellent feasibility of UHF MR-guided radiotherapy for intermediate-risk prostate cancer patients and acceptable toxicity rates in our preliminary study. Randomized controlled studies with long-term follow-up are warranted to detect possible advantages over current state-of-the-art RT techniques. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
174. Toxicity and Efficacy of Local Ablative, Image-guided Radiotherapy in Gallium-68 Prostate-specific Membrane Antigen Targeted Positron Emission Tomography–staged, Castration-sensitive Oligometastatic Prostate Cancer: The OLI-P Phase 2 Clinical Trial
- Author
-
Hölscher, Tobias, Baumann, Michael, Kotzerke, Jörg, Zöphel, Klaus, Paulsen, Frank, Müller, Arndt-Christian, Zips, Daniel, Koi, Lydia, Thomas, Christian, Löck, Steffen, Krause, Mechthild, Wirth, Manfred, and Lohaus, Fabian
- Abstract
Local ablative radiotherapy (aRT) of oligometastatic prostate cancer (PCa) is very promising and has become a focus of current clinical research.
- Published
- 2021
- Full Text
- View/download PDF
175. Integrative assessment of brain and bone invasion in meningioma patients.
- Author
-
Zwirner, Kerstin, Paulsen, Frank, Schittenhelm, Jens, Gepfner-Tuma, Irina, Tabatabai, Ghazaleh, Behling, Felix, Skardelly, Marco, Bender, Benjamin, Zips, Daniel, and Eckert, Franziska
- Subjects
- *
SKULL base , *BRAIN , *BONES , *OPTIC nerve , *INTENSITY modulated radiotherapy , *CANCER invasiveness , *MENINGIOMA - Abstract
Background: Various prognostic factors have been suggested in meningioma patients including WHO grading, brain invasion and bone involvement, for instance. Brain invasion was included as an independent criterion in the recent WHO classification. However, assessability of brain or bone involvement is often limited or varies between histopathologic, operative and imaging reports. Objective of our study was to investigate prognostic values including brain and bone involvement according to different clinical approaches.Methods: A cohort of 111 patients was treated with primary, adjuvant or salvage irradiation between 2008 and 2017 using intensity-modulated radiotherapy. Positron-emission tomography (PET) was available for treatment planning in 81% of patients. Clinical data were extracted from the medical reports. Brain and bone involvement were stratified separately according to histopathologic, operative and imaging reports as well as judged in synopsis.Results: WHO grade I tumours, lower estimated proliferation index, primary versus recurrence treatment and localization (i.e. skull base, optic nerve sheath) were beneficial prognostic factors for local control. Judgement of brain and bone invasion partly differed between diagnostic modalities. In synopsis, brain or bone invasion did not show a significant influence on local control rates.Conclusions: Several previously described prognostic factors could be reproduced. However, partly divergent histopathological, surgical and image-based judgements could be found in regard to brain and bone invasion and all methods imply limitations. Therefore, we suggest a particular, complemental synopsis judgement. In synopsis, brain or bone involvement did not coherently impair local control in our irradiated patients. This might be explained by elaborate radiation techniques and PET-based treatment planning. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
176. Norwegian Settlers in Alberta
- Author
-
Lund, Jens, primary, Brunvand, Jan Harold, additional, Paulsen, Frank M., additional, Houser, George J., additional, and Salo, Matt T., additional
- Published
- 1978
- Full Text
- View/download PDF
177. Targeted therapies in retinoblastoma: GD2-directed immunotherapy following autologous stem cell transplantation and evaluation of alternative target B7-H3.
- Author
-
Eichholz, Thomas, Heubach, Florian, Arendt, Anne-Marie, Seitz, Christian, Brecht, Ines B., Ebinger, Martin, Flaadt, Tim, Süsskind, Daniela, Richter, Lisa, Hülsenbeck, Isabel, Zerweck, Leonie, Göricke, Sophia, Paulsen, Frank, Dombrowski, Frank, Flotho, Christian, Schönberger, Stefan, Ketteler, Petra, Schulte, Johannes, and Lang, Peter
- Abstract
Background: GD2-directed immunotherapy is highly effective in the treatment of high-risk neuroblastoma (NB), and might be an interesting target also in other high-risk tumors. Methods: The German-Austrian Retinoblastoma Registry, Essen, was searched for patients, who were treated with anti-GD2 monoclonal antibody (mAb) dinutuximab beta (Db) in order to evaluate toxicity, response and outcome in these patients. Additionally, we evaluated anti-GD2 antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) in retinoblastoma cell lines in vitro. Furthermore, in vitro cytotoxicity assays directed against B7-H3 (CD276), a new identified potential target in RB, were performed. Results: We identified four patients with relapsed stage IV retinoblastoma, who were treated with Db following autologous stem cell transplantation (ASCT). Two out of two evaluable patients with detectable tumors responded to immunotherapy. One of these and another patient who received immunotherapy without residual disease relapsed 10 and 12 months after start of Db. The other patients remained in remission until last follow-up 26 and 45 months, respectively. In vitro, significant lysis of RB cell lines by ADCC and CDC with samples from patients and healthy donors and anti-GD2 and anti-CD276-mAbs were demonstrated. Conclusion: Anti-GD2-directed immunotherapy represents an additional therapeutic option in high-risk metastasized RB. Moreover, CD276 is another target of interest. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
178. Mathematical Notes
- Author
-
Franklin, S. P., primary, Brenner, J. L., additional, Utz, W. R., additional, Hill, Paul D., additional, Evans, Trevor, additional, Paulsen, Frank, additional, Gordon, Basil, additional, Carlitz, L., additional, Larsson, Robert D., additional, Henrici, Peter, additional, Lass, Harry, additional, and Solloway, Carleton B., additional
- Published
- 1961
- Full Text
- View/download PDF
179. Evolution of a Meningothelial Meningioma: From WHO Grade 1 to Anaplastic Grade 3 with Extracranial Metastasis Including Extensive Liver Metastasis.
- Author
-
Ruff, Christer, Bombach, Paula, Gohla, Georg, Hauser, Till-Karsten, Paulsen, Frank, Farhang, Nick, Boesmueller, Hans, Beschorner, Rudi, and Bongers, Malte
- Subjects
- *
LIVER metastasis , *MENINGIOMA , *METASTASIS , *CANCER relapse , *MTOR inhibitors , *ANAPLASTIC thyroid cancer - Abstract
A 61-year-old patient was diagnosed with a left-sided falx meningioma. Histopathological analysis following extirpation showed a meningothelial meningioma ZNS WHO grade 1 with sparse mitoses. Over the course of 12 years, the patient received irradiation (54.0 Gy), peptide radio-receptor therapy (177Lu-DOMITATE) and targeted therapy (mTOR inhibitor). Follow-up imaging revealed an increased size of the residual tumor. Due to increased liver function parameters, imaging of the liver was performed, showing widespread space-occupying lesions with atypical appearance. Biopsy revealed metastasis of the meningioma, now with 2.7 mitoses/mm2, necrosis and homozygous CDKN2A/B deletion, corresponding to an anaplastic CNS meningioma WHO grade 3. A second small meningioma on the left petroclival side has been consistent in size over 12 years. Metastatic meningiomas pose a pertinent clinical challenge due to poor prognosis. The lung, bone, liver and cervical lymph nodes are the most common sites of extracranial metastasis. According to the World Health Organization criteria, the most important predictive factor for recurrence and metastasis is the tumor grade. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
180. Multimodal Therapy with Consolidating Haploidentical Stem Cell Transplantation and Dinutuximab Beta for Patients with High-Risk Neuroblastoma and Central Nervous System Relapse.
- Author
-
Flaadt, Tim, Ebinger, Martin, Schreiber, Malin, Ladenstein, Ruth L., Simon, Thorsten, Lode, Holger N., Hero, Barbara, Schuhmann, Martin U., Schäfer, Jürgen, Paulsen, Frank, Timmermann, Beate, Eggert, Angelika, and Lang, Peter
- Subjects
- *
NEUROBLASTOMA , *STEM cell transplantation , *CENTRAL nervous system , *COMBINED modality therapy - Abstract
Despite highly intensive multimodality treatment regimens, the prognosis of patients with high-risk neuroblastoma (HRNB) and central nervous system (CNS) relapse remains poor. We retrospectively reviewed data from 13 patients with HRNB and CNS relapse who received multimodal therapy with consolidating haploidentical stem cell transplantation (haplo-SCT) followed by dinutuximab beta ± subcutaneous interleukin-2 (scIL-2). Following individual relapse treatment, patients aged 1−21 years underwent haplo-SCT with T/B-cell-depleted grafts followed by dinutuximab beta 20 mg/m2/day × 5 days for 5–6 cycles. If a response was demonstrated after cycle 5 or 6, patients received up to nine treatment cycles. After haplo-SCT, eight patients had a complete response, four had a partial response, and one had a stable disease. All 13 patients received ≥3 cycles of immunotherapy. At the end of the follow-up, 9/13 patients (66.7%) demonstrated complete response. As of July 2023, all nine patients remain disease-free, with a median follow-up time of 5.1 years since relapse. Estimated 5-year event-free and overall survival rates were 55.5% and 65.27%, respectively. Dinutuximab beta ± scIL-2 following haplo-SCT is a promising treatment option with a generally well-tolerated safety profile for patients with HRNB and CNS relapse. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
181. Immunosuppressive Total Nodal Irradiation-Based Reconditioning Regimens After Graft Rejection or Graft Failure in Pediatric Patients Treated With Myeloablative Allogeneic Hematopoietic Cell Transplantation.
- Author
-
Wegener, Daniel, Lang, Peter, Paulsen, Frank, Weidner, Nicola, Zips, Daniel, Ebinger, Martin, Holzer, Ursula, Döring, Michaela, Basu, Oliver, Gruhn, Bernd, Wittig, Andrea, Teltschik, Heiko-Manuel, Handgretinger, Rupert, and Heinzelmann, Frank
- Subjects
- *
CELL transplantation , *GRAFT rejection , *MULTIPLE organ failure , *DISEASE relapse , *BONE marrow - Abstract
Purpose: This retrospective analysis aimed to address the efficacy of total nodal irradiation (TNI)-based reconditioning regimens in pediatric patients with graft failure/rejection after allogeneic hematopoietic cell transplantation.Methods and Materials: Thirty-three pediatric patients with malignant (n = 25) and nonmalignant diseases (n = 8) were treated with a TNI-based reconditioning regimen. All patients received a 7-Gy single dose combined with anti-T lymphocyte antibody OKT3 (n = 16), anti-thymocyte globulin (n = 24), fludarabine (n = 31), and/or thiotepa (n = 28), followed by an infusion of peripheral blood stem cells (n = 31) or bone marrow transplant (n = 2). Twenty-eight of 33 patients had haploidentical family donors.Results: After a median of 11 days, engraftment was seen in 32 of 33 children. Two children died 34 days after retransplantation because of either disease relapse or treatment-related multiple organ failure. Severe acute toxicity was reported in only 1 child (systemic inflammatory response syndrome-like reaction; recovery after cortisone treatment). The average follow-up was 60.2 months (range, 1.1-162.5 months). Event-free and overall survival rates at 2/5 years follow-up were 62.0%/58.6% and 65.1%/61.7%, respectively. Despite sustained engraftment, 12 patients died from disease relapse (n = 3), Moschkowitz syndrome (n = 1), or multiple organ failure (n = 8). Follow-up data were available for 18 of 21 survivors, with a median follow-up of 92.8 months (range, 3.6-162.5 months). Hypothyroidism was present in 78.6% of patients, and sex/growth hormonal insufficiencies were reported for 37.5%. Mean forced expiratory volume in 1 second after TNI was 84%; mean vital capacity was 79%. Severe growth failure (<3rd percentile) occurred in 28.6% (height) and 35.7% (weight) of patients. No secondary malignancies were reported.Conclusions: In the high-risk group of patients with graft failure/rejection after allogeneic hematopoietic cell transplantation, the TNI-based reconditioning regimen seems to allow sustained engraftment combined with a favorable toxicity profile, leading to long-term event-free and overall survival. Late toxicity after a median follow-up of over 7.5 years includes growth failure, manageable hormonal deficiencies, and a low risk of decrease of lung function. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
182. Increasing Patient Safety and Treatment Quality by Using Intraoperative MRI for Organ-Preserving Tumor Resection and High-Dose Rate Brachytherapy in Children with Bladder/Prostate and Perianal Rhabdomyosarcoma.
- Author
-
Schmidt, Andreas, Roder, Constantin, Eckert, Franziska, Baumann, David, Niyazi, Maximilian, Fideler, Frank, Ernemann, Ulrike, Tatagiba, Marcos, Schäfer, Jürgen, Urla, Cristian, Scherer, Simon, Fuchs, Jörg, Paulsen, Frank, and Bender, Benjamin
- Subjects
- *
MEDICAL quality control , *RHABDOMYOSARCOMA , *INTRAOPERATIVE care , *MAGNETIC resonance imaging , *PRESERVATION of organs, tissues, etc. , *ANAL tumors , *TREATMENT effectiveness , *RADIOISOTOPE brachytherapy , *COMBINED modality therapy , *PATIENT safety , *PROSTATE tumors , *CHILDREN ,BLADDER tumors - Abstract
Simple Summary: The combination treatment of organ-preserving tumor resection and brachytherapy in children with bladder/prostate and perianal rhabdomyosarcoma can reduce therapy-associated side effects while maintaining excellent oncological outcome. This highly individualized hybrid treatment concept poses specific challenges for all clinicians involved in the local treatment. The aim of this study was to determine whether the use of an intraoperative MRI can improve the clinical workflow. These findings may have a positive impact on the treatment quality and patient safety of children with bladder/prostate and perianal RMS. In children with bladder/prostate (BP) and perianal rhabdomyosarcoma (RMS), we use a hybrid treatment concept for those suitable, combining organ-preserving tumor resection and high-dose rate brachytherapy (HDR-BT). This treatment concept has been shown to improve outcomes. However, it is associated with specific challenges for the clinicians. The exact position of the tubes for BT is a prerequisite for precise radiotherapy. It can finally be determined only with an MRI or CT scan. We evaluated the use of an intraoperative MRI (iMRI) to control the position of the BT tubes and for radiotherapy planning in all patients with BP and perianal RMS who received the above-mentioned combination therapy in our department since January 2021. iMRI was used in 12 children. All tubes were clearly localized. No adverse events occurred. In all 12 children, radiotherapy could be started on time. In a historical cohort without iMRI, this was not possible in 3 out of 20 children. The use of iMRI in children with BP and perianal RMS improved patient safety and treatment quality. This technology has proven to be successful for the patient population we have defined and has become a standard procedure in our institution. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
183. Detailed functional results after bladder-preserving surgery and high-dose-rate brachytherapy in pediatric bladder/prostate rhabdomyosarcoma.
- Author
-
Ellerkamp, Verena, Schmidt, Andreas, Warmann, Steven W., Eckert, Franziska, Schaefer, Juergen, Paulsen, Frank, and Fuchs, Joerg
- Subjects
- *
HIGH dose rate brachytherapy , *RADIOISOTOPE brachytherapy , *BLADDER , *RHABDOMYOSARCOMA , *PROSTATE , *NEOADJUVANT chemotherapy - Abstract
Purpose: In pediatric bladder/prostate-rhabdomyosarcoma, the rate of bladder preservation after neoadjuvant chemotherapy is high, with an excellent oncological outcome. Information about functional urological long-term outcomes is rare. Methods: Data of all patients who had undergone bladder-preserving surgery with or without brachytherapy at our institution between 2009 and 2020 were analyzed retrospectively. Detailed urological function was assessed focusing on age-related continence, bladder capacity and urodynamic findings. Results: We identified 40 patients, median age at surgery of 27 months (range 9–191), and 32 patients additionally received postoperative high-dose-rate brachytherapy. The median follow-up was 32.5 months (range 6–125). The bladder capacity increased from median 66.7% (21.1–180) of expected bladder capacity related to age 3 months after surgery to 87.4% (58.1–181.8) 9 months after surgery. In the group of aged > 6-year-old, continence was 94% (83% with brachytherapy, 100% without brachytherapy). Erectile function was normal in 92% (90% with brachytherapy, 100% without brachytherapy). Bladder capacity was more than 65% expected bladder capacity related to age in 70% (60% with brachytherapy, 86% without brachytherapy). 65% of all patients need neither anticholinergic drugs nor low-dose antibiotics (63% with brachytherapy, 71% without brachytherapy). Conclusions: Bladder preservation with good functional outcome can be achieved in localized bladder/prostate-rhabdomyosarcoma. In selected cases, supportive brachytherapy additionally contributes to an improvement in the oncological outcome with calculable risks for bladder and erectile function. Careful urological aftercare should be a fixed priority after oncological follow-ups. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
184. The prognostic role of the immunohistochemical expression of S100 in meningiomas.
- Author
-
Behling, Felix, Fodi, Christina, Skardelly, Marco, Paulsen, Frank, Tabatabai, Ghazaleh, Honegger, Jürgen, Tatagiba, Marcos, and Schittenhelm, Jens
- Subjects
- *
IMMUNOSTAINING , *PROGRESSION-free survival , *DISEASE relapse , *UNIVARIATE analysis ,TUMOR surgery - Abstract
Background: Despite best clinical management, meningioma patients experience tumor recurrence. Efforts have been made to improve the prognostic stratification of meningiomas. Recently, a multi-faceted molecular classification suggested that the marker S100 is associated with a favorable outcome, making a further analysis in a larger cohort interesting. Materials and methods: The immunohistochemical staining for S100 was analyzed in 1669 paraffin-embedded meningioma samples. The distribution and association with clinical data and progression-free survival via radiographic tumor recurrence were assessed. Results: Of 1669 cases, 218 tumors showed strong S100 expression (13.1%). A significantly higher frequency of S100 positive meningiomas was observed in meningiomas of female patients, tumors with spinal and convexity/falx location, primary tumor surgery, NF2, higher extent of resection, lower WHO CNS grade, adjuvant radiotherapy and recurrence-free tumors during follow-up. Univariate analysis revealed a favorable progression-free survival for meningiomas with S100 expression (p = 0.0059) but not in the multivariate analysis. Higher S100 frequency was independently associated with female gender (p = 0.0003), NF2 (p < 0.0001), tumor location (p < 0.0001) and lower WHO CNS grade (p = 0.0133). Conclusions: The positive prognostic impact of S100 is mostly attributed to the confounding clinical factors gender, tumor location, NF2 status and WHO CNS grade. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
185. External validation of a prognostic model estimating the survival of patients with recurrent high-grade gliomas after reirradiation.
- Author
-
Müller, Klaus, Henke, Guido, Compter, Inge, von Bueren, André O., Friedrich, Carsten, Janssens, Geert, Kramm, Christof M., Hundsberger, Thomas, Paulsen, Frank, Kortmann, Rolf-Dieter, Zwiener, Isabella, and Baumert, Brigitta G.
- Abstract
Purpose We aimed to validate a controversial prognostic model for the survival of relapsed malignant glioma patients after reirradiation with an independent, multicentric patient cohort. Methods and materials A total of 165 malignant glioma patients underwent reirradiation at 4 different institutions between 1994 and 2012. Twenty-two patients had a good (score 1), 44 had a moderate (score 2), and 99 had a poor prognosis (score 3 or 4). Four statistical methods were used to validate the prognostic model: First, we compared survival according to prognostic group in the construction and the validation cohort by visual comparison of the respective Kaplan-Meier plots. Second, discrimination was quantified by calculating hazard ratios for death for each prognostic group, with the worst prognostic group serving as the reference. Calibration was assessed by a calibration plot for the time point 12 months after reirradiation. Finally, we compared the predictive performance of the score and a hypothetical prognostic model ignoring all predictor variables over time by means of a prediction error curve. Results On visual validation, the survival curves of the 3 patient groups with good, moderate, and poor prognoses nicely separated from each other. Median survival rates after reirradiation were 17.9, 9.0, and 7.7 months in the patient groups with good, moderate, and poor prognosis, respectively. Hazard ratios confirmed satisfactory discrimination. Calibration was satisfactory for all and most accurate for the worst prognostic group. The score improved the prognostic performance in comparison to the “zero-model.” Conclusions We successfully validated a prognostic model for the survival of malignant glioma patients after reirradiation with a multicentric, independent dataset. Being reliable and easy to handle, the model can be useful in personalized patient counseling and clinical decision-making. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
186. Endoresection with adjuvant ruthenium brachytherapy for selected uveal melanoma patients - the Tuebingen experience.
- Author
-
Süsskind, Daniela, Dürr, Carina, Paulsen, Frank, Kaulich, Theodor, and Bartz‐Schmidt, Karl U.
- Subjects
- *
RADIOISOTOPE brachytherapy , *UVEA cancer , *UVEA , *SURGICAL excision , *HEALTH outcome assessment , *TUMOR treatment , *TUMORS - Abstract
Purpose To evaluate the treatment of selected patients with uveal melanoma with endoresection and adjuvant ruthenium brachytherapy. Methods Thirty-five patients with uveal melanoma not suitable for ruthenium plaque monotherapy were treated with endoresection and adjuvant ruthenium brachytherapy between January 2001 and October 2013. Recurrence-free survival, globe retention, course of visual acuity ( VA), occurrence of therapy-related complications and metastasis-free and overall survival were analysed retrospectively. Results Eight patients (22.9%) had a tumour recurrence after a median follow-up of 49.5 months (range: 21-134 months). Enucleation was necessary in eight patients. Thirty-two patients (91%) had a loss of VA with a median loss of nine lines (range: 0 to −39 lines); VA was stable in three patients and no patients had a gain in VA. Four patients (11.4%) developed radiation retinopathy. Metastases were detected in seven patients (20.0%) during follow-up. The occurrence of metastasis was significantly associated with monosomy 3 (p < 0.0001). Twenty-four patients (68.6%) were alive at the end of follow-up. Five patients (14.3%) died because of uveal melanoma (UM) metastasis. Conclusions Endoresection with adjuvant ruthenium brachytherapy is an option for selected patients with UM who cannot be treated with brachytherapy as monotherapy. About two-thirds of eyes can be retained long term without recurrences. Visual acuity cannot be maintained in most cases, and may even decrease considerably. Radiation complications are comparatively rare and not a significant problem. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
187. In Reply.
- Author
-
Suesskind, Daniela and Paulsen, Frank
- Published
- 2014
- Full Text
- View/download PDF
188. Postoperative complications and oncologic outcomes after multimodal therapy of localized high risk soft tissue sarcoma.
- Author
-
Potkrajcic, Vlatko, Kolbenschlag, Jonas, Sachsenmaier, Saskia, Daigeler, Adrien, Ladurner, Ruth, Golf, Alexander, Gani, Cihan, Zips, Daniel, Paulsen, Frank, and Eckert, Franziska
- Subjects
- *
SARCOMA , *COMBINED modality therapy , *RADIOTHERAPY , *SURGICAL complications , *PROGNOSIS , *INJURY risk factors - Abstract
Background: Standard therapy for localized high-risk soft tissue sarcoma includes surgical resection and neoadjuvant or adjuvant radiation therapy (± chemotherapy and locoregional hyperthermia). No difference in oncologic outcomes for patients treated with neoadjuvant and adjuvant radiation therapy was reported, whereas side effect profiles differ. The aim of this analysis was to analyse oncologic outcomes and postoperative complications in patients treated with multimodal treatment. Methods: Oncologic outcomes and major wound complications (MWC, subclassified as wound healing disorder, infection, abscess, fistula, seroma and hematoma) were evaluated in 74 patients with localized high-risk soft tissue sarcoma of extremities and trunk undergoing multimodal treatment, and also separately for the subgroup of lower extremity tumors. Clinical factors and treatment modalities (especially neoadjuvant vs. adjuvant radiotherapy) were evaluated regarding their prognostic value and impact on postoperative wound complications. Results: Oncologic outcomes were dependent on number of high risk features (tumor size, depth to superficial fascia and grading), but not on therapy sequencing (however with higher risk patients in the neoadjuvant group). Different risk factors influenced different subclasses of wound healing complications. Slightly higher MWC-rates were observed in patients treated with neoadjuvant therapy, compared to adjuvant radiotherapy, although only with a trend to statistical significance (31.8% vs. 13.3%, p = 0.059). However, except for wound infections, no significant difference for other subclasses of postoperative complications was observed between neoadjuvant and adjuvant therapy. Diabetes was confirmed as a major risk factor for immune-related wound complications. Conclusion: Rates of major wound complications in this cohort are comparable to published data, higher rates of wound infections were observed after neoadjuvant radiotherapy. Tumor localization, patient age and diabetes seem to be major risk factors. The number of risk factors for high risk soft tissue sarcoma seem to influence DMFS. Neoadjuvant treatment increases the risk only for wound infection treated with oral or intravenous antibiotic therapy and appears to be a safe option at an experienced tertiary center in absence of other risk factors. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
189. Nodal Clearance Rate and Long-Term Efficacy of Individualized Sentinel Node-Based Pelvic Intensity Modulated Radiation Therapy for High-Risk Prostate Cancer.
- Author
-
Müller, Arndt-Christian, Eckert, Franziska, Paulsen, Frank, Zips, Daniel, Stenzl, Arnulf, Schilling, David, Alber, Markus, Bares, Roland, Martus, Peter, Weckermann, Dorothea, Belka, Claus, and Ganswindt, Ute
- Subjects
- *
SENTINEL lymph nodes , *INTENSITY modulated radiotherapy , *PROSTATE cancer risk factors , *CANCER radiotherapy , *KAPLAN-Meier estimator , *FOLLOW-up studies (Medicine) - Abstract
Purpose: To assess the efficacy of individual sentinel node (SN)-guided pelvic intensity modulated radiation therapy (IMRT) by determining nodal clearance rate [(n expected nodal involvement - n observed regional recurrences)/n expected nodal involvement] in comparison with surgically staged patients.Methods and Materials: Data on 475 high-risk prostate cancer patients were examined. Sixty-one consecutive patients received pelvic SN-based IMRT (5 × 1.8 Gy/wk to 50.4 Gy [pelvic nodes + individual SN] and an integrated boost with 5 × 2.0 Gy/wk to 70.0 Gy to prostate + [base of] seminal vesicles) and neo-/adjuvant long-term androgen deprivation therapy; 414 patients after SN-pelvic lymph node dissection were used to calculate the expected nodal involvement rate for the radiation therapy sample. Biochemical control and overall survival were estimated for the SN-IMRT patients using the Kaplan-Meier method. The expected frequency of nodal involvement in the radiation therapy group was estimated by imputing frequencies of node-positive patients in the surgical sample to the pattern of Gleason, prostate-specific antigen, and T category in the radiation therapy sample.Results: After a median follow-up of 61 months, 5-year OS after SN-guided IMRT reached 84.4%. Biochemical control according to the Phoenix definition was 73.8%. The nodal clearance rate of SN-IMRT reached 94%. Retrospective follow-up evaluation is the main limitation.Conclusions: Radiation treatment of pelvic nodes individualized by inclusion of SNs is an effective regional treatment modality in high-risk prostate cancer patients. The pattern of relapse indicates that the SN-based target volume concept correctly covers individual pelvic nodes. Thus, this SN-based approach justifies further evaluation, including current dose-escalation strategies to the prostate in a larger prospective series. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
190. Brachytherapy for rhabdomyosarcoma: Survey of international clinical practice and development of guidelines.
- Author
-
Dávila Fajardo, Raquel, Scarzello, Giovanni, Gaze, Mark N, Boterberg, Tom, Cameron, Alison, Fuchs, Joerg, Guérin, Florent, Hoskin, Peter, Krasin, Matthew J, Kroon, Petra, Magelssen, Henriette, Mercke, Claes, Merks, Johannes H.M., Paulsen, Frank, Pommier, Pascal, Ramos, Monica, Rees, Helen, Rogers, Tim, Schmid, Maximilian, and Seitz, Guido
- Subjects
- *
RADIOISOTOPE brachytherapy , *RHABDOMYOSARCOMA , *SARCOMA , *LITERATURE reviews ,TUMOR surgery - Abstract
• Carefully selected RMS pediatric patients can be treated with brachytherapy. • The use of brachytherapy in this population has progressively increased. • Brachytherapy can limit the long-term side effects related to radiation. • Highly specialized experienced teams are needed to deliver the service. • Harmonization and international consensus is most required for an optimal care. The purpose of this study was to address the lack of published data on the use of brachytherapy in pediatric rhabdomyosarcoma by describing current practice as starting point to develop consensus guidelines. An international expert panel on the treatment of pediatric rhabdomyosarcoma comprising 24 (pediatric) radiation oncologists, brachytherapists and pediatric surgeons met for a Brachytherapy Workshop hosted by the European paediatric Soft tissue Sarcoma Study Group (EpSSG). The panel's clinical experience, the results of a previously distributed questionnaire, and a review of the literature were presented. The survey indicated the most common use of brachytherapy to be in combination with tumor resection, followed by brachytherapy as sole local therapy modality. HDR was increasingly deployed in pediatric practice, especially for genitourinary sites. Brachytherapy planning was mostly by 3D imaging based on CT. Recommendations for patient selection, treatment requirements, implant technique, delineation, dose prescription, dose reporting and clinical management were defined. Consensus guidelines for the use of brachytherapy in pediatric rhabdomyosarcoma have been developed through multicenter collaboration establishing the basis for future work. These have been adopted for the open EpSSG overarching study for children and adults with Frontline and Relapsed RhabdoMyoSarcoma (FaR-RMS). [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
191. The European Particle Therapy Network (EPTN) consensus on the follow-up of adult patients with brain and skull base tumours treated with photon or proton irradiation.
- Author
-
De Roeck, Laurien, van der Weide, Hiska L., Eekers, Daniëlle B.P., Kramer, Miranda C., Alapetite, Claire, Blomstrand, Malin, Burnet, Neil G., Calugaru, Valentin, Coremans, Ida E.M., Di Perri, Dario, Harrabi, Semi, Iannalfi, Alberto, Klaver, Yvonne L.B., Langendijk, Johannes A., Romero, Alejandra Méndez, Paulsen, Frank, Roelofs, Erik, de Ruysscher, Dirk, Timmermann, Beate, and Vitek, Pavel
- Subjects
- *
SKULL base , *BRAIN tumors , *CANCER patients , *PHOTONS , *TUMORS - Abstract
[Display omitted] • Consensus on time- and endpoints to evaluate toxicity on relevant outcome domains. • This framework will facilitate international collaboration and data collection. • Goal: develop individualized risk assessments for brain tumour patients after RT. • An interactive spreadsheet is available at www.cancerdata.org. Treatment-related toxicity after irradiation of brain tumours has been underreported in the literature. Furthermore, there is considerable heterogeneity on how and when toxicity is evaluated. The aim of this European Particle Network (EPTN) collaborative project is to develop recommendations for uniform follow-up and toxicity scoring of adult brain tumour patients treated with radiotherapy. A Delphi method-based consensus was reached among 24 international radiation-oncology experts in the field of neuro-oncology concerning the toxicity endpoints, evaluation methods and time points. In this paper, we present a basic framework for consistent toxicity scoring and follow-up, using multiple levels of recommendation. Level I includes all recommendations that are considered minimum of care, whereas level II and III are optional evaluations in the advanced clinical or research setting, respectively. Per outcome domain, the clinical endpoints and evaluation methods per level are listed. Where relevant, the organ at risk threshold doses for recommended referral to specific organ specialists are defined. These consensus-based recommendations for follow-up will enable the collection of uniform toxicity data of brain tumour patients treated with radiotherapy. With adoptation of this standard, collaboration will be facilitated and we can further propel the research field of radiation-induced toxicities relevant for these patients. An online tool to implement this guideline in clinical practice is provided at www.cancerdata.org. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
192. Retrospective analysis of recurrence patterns and clinical outcome of grade II meningiomas following postoperative radiotherapy.
- Author
-
Hoffmann, Elgin, Clasen, Kerstin, Frey, Bettina, Ehlers, Jakob, Behling, Felix, Skardelly, Marco, Bender, Benjamin, Schittenhelm, Jens, Reimold, Matthias, Tabatabai, Ghazaleh, Zips, Daniel, Eckert, Franziska, and Paulsen, Frank
- Subjects
- *
TREATMENT effectiveness , *PROGNOSIS , *VOLUMETRIC-modulated arc therapy , *SOMATOSTATIN receptors , *DISEASE relapse , *INTENSITY modulated radiotherapy - Abstract
Background: Atypical meningiomas exhibit a high tendency for tumor recurrence even after multimodal therapy. Information regarding recurrence patterns after additive radiotherapy is scarce but could improve radiotherapy planning and therapy decision. We conducted an analysis of recurrence patterns with regard to target volumes and dose coverage assessing target volume definition and postulated areas of tumor re-growth origin. Prognostic factors contributing to relapse were evaluated. Methods: The clinical outcome of patients who had completed additive, somatostatin receptor (SSTR)-PET/CT-based fractionated intensity-modulated radiotherapy for atypical meningioma between 2007 and 2017 was analyzed. In case of tumor recurrence/progression, treatment planning was evaluated for coverage of the initial target volumes and the recurrent tumor tissue. We proposed a model evaluating the dose distribution in postulated areas of tumor re-growth origin. The median of proliferation marker MIB-1 was assessed as a prognostic factor for local progression and new distant tumor lesions. Results: Data from 31 patients who had received adjuvant (n = 11) or salvage radiotherapy (n = 20) were evaluated. Prescribed dose ranged from 54.0 to 60.0 Gy. Local control at five years was 67.9%. Analysis of treatment plans of the eight patients experiencing local failure proved sufficient extent of target volumes and coverage of the prescribed dose of at least 50.0 Gy as determined by mean dose, D98, D2, and equivalent uniform dose (EUD) of all initial target volumes, postulated growth-areas, and areas of recurrent tumor tissue. In all cases, local failure occurred in high-dose volumes. Tumors with a MIB-1 expression above the median (8%) showed a higher tendency for re-growth. Conclusions: The model showed adequate target volume and relative dose distribution but absolute dose appears lower in recurrent tumors without reaching statistical significance. This might provide a rationale for dose escalation studies. Biological factors such as MIB-1 might aid patients' stratification for dose escalation. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
193. Update of the EPTN atlas for CT- and MR-based contouring in Neuro-Oncology.
- Author
-
Eekers, Daniëlle B.P., Di Perri, Dario, Roelofs, Erik, Postma, Alida, Dijkstra, Jeanette, Ajithkumar, Thankamma, Alapetite, Claire, Blomstrand, Malin, Burnet, Neil G, Calugaru, Valentin, Compter, Inge, Coremans, Ida E.M., Harrabi, Semi, Iannalfi, Alberto, Klaver, Yvonne L.B., Lambrecht, Maarten, Romero, Alejandra Méndez, Paulsen, Frank, Timmermann, Beate, and Vitek, Pavel
- Subjects
- *
COMPUTED tomography , *MEDICAL research , *MAGNETIC resonance , *COGNITIVE ability , *MAGNETIC resonance imaging - Abstract
• Neuro contouring atlas to decrease inter- and intra-observer OAR delineation. • The updated atlas was reviewed and approved by 28 experts in the field. • Cognitive functioning and radiological changes related OARs were added. • The atlas (25 OARs) is freely available online on www.cancerdata.org. • Three- dimensional (3D) rendered films are included. To update the digital online atlas for organs at risk (OARs) delineation in neuro-oncology based on high-quality computed tomography (CT) and magnetic resonance (MR) imaging with new OARs. In this planned update of the neurological contouring atlas published in 2018, ten new clinically relevant OARs were included, after thorough discussion between experienced neuro-radiation oncologists (RTOs) representing 30 European radiotherapy-oncology institutes. Inclusion was based on daily practice and research requirements. Consensus was reached for the delineation after critical review. Contouring was performed on registered CT with intravenous (IV) contrast (soft tissue & bone window setting) and 3 Tesla (T) MRI (T1 with gadolinium & T2 FLAIR) images of one patient (1 mm slices). For illustration purposes, delineation on a 7 T MRI without IV contrast from a healthy volunteer was added. OARs were delineated by three experienced RTOs and a neuroradiologist based on the relevant literature. The presented update of the neurological contouring atlas was reviewed and approved by 28 experts in the field. The atlas is available online and includes in total 25 OARs relevant to neuro-oncology, contoured on CT and MRI T1 and FLAIR (3 T & 7 T). Three-dimensional (3D) rendered films are also available online. In order to further decrease inter- and intra-observer OAR delineation variability in the field of neuro-oncology, we propose the use of this contouring atlas in photon and particle therapy, in clinical practice and in the research setting. The updated atlas is freely available on www.cancerdata.org. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
194. ERGO2: A Prospective, Randomized Trial of Calorie-Restricted Ketogenic Diet and Fasting in Addition to Reirradiation for Malignant Glioma.
- Author
-
Voss, Martin, Wagner, Marlies, von Mettenheim, Nina, Harter, Patrick N., Wenger, Katharina J., Franz, Kea, Bojunga, Jörg, Vetter, Manuela, Gerlach, Ruediger, Glatzel, Michael, Paulsen, Frank, Hattingen, Elke, Baehr, Oliver, Ronellenfitsch, Michael W., Fokas, Emmanouil, Imhoff, Detlef, Steinbach, Joachim P., Rödel, Claus, and Rieger, Johannes
- Subjects
- *
LOW-calorie diet , *GLIOMAS , *KETOGENIC diet , *CLINICAL trials , *EPILEPSY , *GLIOMA treatment , *BRAIN tumor treatment , *BLOOD sugar analysis , *FASTING , *RESEARCH , *BODY weight , *RESEARCH methodology , *CANCER relapse , *PROGNOSIS , *MEDICAL cooperation , *EVALUATION research , *DIET therapy , *TREATMENT effectiveness , *BRAIN tumors , *COMPARATIVE studies , *RANDOMIZED controlled trials , *QUALITY of life , *SEIZURES (Medicine) , *COMBINED modality therapy , *ACIDOSIS , *LONGITUDINAL method - Abstract
Purpose: ERGO2 is the first randomized clinical trial on a calorically restricted ketogenic diet (KD) and intermittent fasting (KD-IF) in addition to reirradiation for recurrent malignant gliomas.Methods and Materials: Fifty patients were randomized 1:1 to reirradiation combined with either a calorically unrestricted diet or KD-IF. The KD-IF schedule included 3 days of KD (21-23 kcal/kg/d), followed by 3 days of fasting and again 3 days of KD. Primary endpoint was progression-free survival (PFS) at 6 months (PFS6). Secondary endpoints were PFS, local PFS, overall survival (OS), frequency of epileptic seizures, rate of ketosis and quality of life.Results: Four patients quit the trial before treatment and 3 patients stopped KD-IF prematurely. Of the 20 patients who completed KD-IF, 17 patients developed ketosis at day 6 and glucose levels declined significantly. KD-IF was well-tolerated with a modest weight loss of -2.1 ± 1.8 kg. No severe adverse events attributable to the diet occurred. PFS6 was not significantly different between the 2 groups (KD-IF: 20%; calorically unrestricted diet: 16%). Similarly, no difference in PFS, local PFS6, or OS was observable. Explorative analysis revealed that patients in the KD-IF group who had a glucose level of less than the median (83.5 mg/dL) on day 6 had significantly longer PFS and OS compared with those above the median (P < .05).Conclusions: KD-IF is feasible and effective in inducing ketosis in heavily pretreated patients with recurrent glioma. However, the short schedule reported here failed to increase the efficacy of reirradiation. CLINICALTRIALS.Gov Number: NCT01754350. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
195. Retrospective analysis of fractionated intensity-modulated radiotherapy (IMRT) in the interdisciplinary management of primary optic nerve sheath meningiomas.
- Author
-
Eckert, Franziska, Clasen, Kerstin, Kelbsch, Carina, Tonagel, Felix, Bender, Benjamin, Tabatabai, Ghazaleh, Zips, Daniel, Thorwarth, Daniela, Frey, Bettina, Becker, Gerd, Wilhelm, Helmut, and Paulsen, Frank
- Subjects
- *
OPTIC nerve , *INTENSITY modulated radiotherapy , *VISUAL acuity , *SCOTOMA , *VISUAL fields , *OPTIC nerve injuries - Abstract
Background: As optic nerve sheath meningiomas (ONSM) are rare, there are no prospective studies. Our retrospective analysis focusses on a cohort of patients with uniform disease characteristics all treated with the same radiotherapy regimen. We describe treatment decision making, radiotherapy planning and detailed neuro-ophthalmological outcome of the patients.Methods: 26 patients with unilateral ONSM extending only to the orbit and the optic canal were evaluated for neuro-ophthalmological outcome. Radiation treatment was planned in a simultaneous integrated boost approach to gross tumor volume (GTV) + 2 mm / 5 mm to 54 Gy / 51 Gy in 1.8 Gy / 1.7 Gy fractions. Follow-up was done by specialized neuro-ophthalmologists. Visual acuity and visual field defects were evaluated after therapy as well as during follow-up.Results: Interdisciplinary treatment decision for patients with ONSM follows a rather complex decision tree. Radiation treatment planning (equivalent uniform dose (EUD), maximum dose to the optic nerve) improved with experience over time. With this patient selection visual acuity as well as visual field improved significantly at first follow-up after treatment. For visual acuity this also applied to patients with severe defects before treatment. Long term evaluation showed 16 patients with improved visual function, 6 were stable, in 4 patients visual function declined. Interdisciplinary case discussion rated the visual decline as radiation-associated in two patients.Conclusions: With stringent patient selection radiotherapy for unilateral primary ONSM to 51 Gy / 54 Gy is safe and leads to significantly improved visual function. Interdisciplinary treatment decision and experience of the radiation oncology team play a major role. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
196. Potential of pre-operative MRI features in glioblastoma to predict for molecular stem cell subtype and patient overall survival.
- Author
-
Eckert, Franziska, Ganser, Katrin, Bender, Benjamin, Schittenhelm, Jens, Skardelly, Marco, Behling, Felix, Tabatabai, Ghazaleh, Hoffmann, Elgin, Zips, Daniel, Huber, Stephan M., and Paulsen, Frank
- Subjects
- *
OVERALL survival , *STEM cells , *GLIOBLASTOMA multiforme , *MAGNETIC resonance imaging , *PROGNOSIS - Abstract
• For a prospective patient cohort, stem cell enriched primary glioblastoma cells were characterized. • Volumetric analysis of preoperative MR imaging was feasible in all cases. • MRI parameters correlate with molecular features of the same tumors. • MRI parameters predict for patient overall survival. A molecular signature based on 10 mRNA abundances that characterizes the mesenchymal-to-proneural phenotype of glioblastoma stem(like) cells (GSCs) enriched in primary culture has been previously established. As this phenotype has been proposed to be prognostic for disease outcome the present study aims to identify features of the preoperative MR imaging that may predict the GSC phenotype of individual tumors. Molecular mesenchymal-to-proneural mRNA signatures and intrinsic radioresistance (SF 4 , survival fraction at 4 Gy) of primary GSC-enriched cultures were associated with survival data and pre-operative MR imaging of the corresponding glioblastoma patients of a prospective cohort (n = 24). The analyzed imaging parameters comprised linear vectors derived from tumor volume, necrotic volume and edema as contoured manually. A necrosis/tumor vector ratio and to a weaker extent the product of this ratio and the edema vector were identified to correlate with the mesenchymal-to-proneural mRNA signature and the SF 4 of the patient-derived GSC cultures. Importantly, both parameter combinations were predictive for overall survival of the whole patient cohort. Moreover, the combination of necrosis/tumor vector ratio and edema vector differed significantly between uni- and multifocally recurring tumors. Features of the preoperative MR images may reflect the molecular signature of the GSC population and might be used in the future as a prognostic factor and for treatment stratification especially in the MGMT promotor-unmethylated sub-cohort of glioblastoma patients. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
197. Radiation dose constraints for organs at risk in neuro-oncology; the European Particle Therapy Network consensus.
- Author
-
Lambrecht, Maarten, Eekers, Daniëlle B.P., Alapetite, Claire, Burnet, Neil G., Calugaru, Valentin, Coremans, Ida E.M., Fossati, Piero, Høyer, Morten, Langendijk, Johannes A., Romero, Alejandra Méndez, Paulsen, Frank, Perpar, Ana, Renard, Laurette, de Ruysscher, Dirk, Timmermann, Beate, Vitek, Pavel, Weber, Damien C., van der Weide, Hiske L., Whitfield, Gillian A., and Wiggenraad, Ruud
- Subjects
- *
RADIATION , *ONCOLOGY , *PARTICLES , *ORGANS (Anatomy) , *TISSUES - Abstract
Purpose For unbiased comparison of different radiation modalities and techniques, consensus on delineation of radiation sensitive organs at risk (OARs) and on their dose constraints is warranted. Following the publication of a digital, online atlas for OAR delineation in neuro-oncology by the same group, we assessed the brain OAR-dose constraints in a follow-up study. Methods We performed a comprehensive search to identify the current papers on OAR dose constraints for normofractionated photon and particle therapy in PubMed, Ovid Medline, Cochrane Library, Embase and Web of Science. Moreover, the included articles’ reference lists were cross-checked for potential studies that met the inclusion criteria. Consensus was reached among 20 radiation oncology experts in the field of neuro-oncology. Results For the OARs published in the neuro-oncology literature, we summarized the available literature and recommended dose constraints associated with certain levels of normal tissue complication probability (NTCP) according to the recent ICRU recommendations. For those OARs with lacking or insufficient NTCP data, a proposal for effective and efficient data collection is given. Conclusion The use of the European Particle Therapy Network-consensus OAR dose constraints summarized in this article is recommended for the model-based approach comparing photon and proton beam irradiation as well as for prospective clinical trials including novel radiation techniques and/or modalities. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
198. The EPTN consensus-based atlas for CT- and MR-based contouring in neuro-oncology.
- Author
-
Eekers, Daniëlle BP, in 't Ven, Lieke, Roelofs, Erik, Postma, Alida, Alapetite, Claire, Burnet, Neil G., Calugaru, Valentin, Compter, Inge, Coremans, Ida E.M., Høyer, Morton, Lambrecht, Maarten, Nyström, Petra Witt, Romero, Alejandra Méndez, Paulsen, Frank, Perpar, Ana, de Ruysscher, Dirk, Renard, Laurette, Timmermann, Beate, Vitek, Pavel, and Weber, Damien C.
- Subjects
- *
ORGANS (Anatomy) , *COMPUTED tomography , *MAGNETIC resonance imaging , *ONCOLOGISTS , *RADIATION - Abstract
Purpose To create a digital, online atlas for organs at risk (OAR) delineation in neuro-oncology based on high-quality computed tomography (CT) and magnetic resonance (MR) imaging. Methods CT and 3 Tesla (3T) MR images (slice thickness 1 mm with intravenous contrast agent) were obtained from the same patient and subsequently fused. In addition, a 7T MR without intravenous contrast agent was obtained from a healthy volunteer. Based on discussion between experienced radiation oncologists, the clinically relevant organs at risk (OARs) to be included in the atlas for neuro-oncology were determined, excluding typical head and neck OARs previously published. The draft atlas was delineated by a senior radiation oncologist, 2 residents in radiation oncology, and a senior neuro-radiologist incorporating relevant available literature. The proposed atlas was then critically reviewed and discussed by European radiation oncologists until consensus was reached. Results The online atlas includes one CT-scan at two different window settings and one MR scan (3T) showing the OARs in axial, coronal and sagittal view. This manuscript presents the three-dimensional descriptions of the fifteen consensus OARs for neuro-oncology. Among these is a new OAR relevant for neuro-cognition, the posterior cerebellum (illustrated on 7T MR images). Conclusion In order to decrease inter- and intra-observer variability in delineating OARs relevant for neuro-oncology and thus derive consistent dosimetric data, we propose this atlas to be used in photon and particle therapy. The atlas is available online at www.cancerdata.org and will be updated whenever required. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
199. Independent validation of a new reirradiation risk score (RRRS) for glioma patients predicting post-recurrence survival: A multicenter DKTK/ROG analysis.
- Author
-
Niyazi, Maximilian, Adeberg, Sebastian, Kaul, David, Boulesteix, Anne-Laure, Bougatf, Nina, Fleischmann, Daniel F., Grün, Arne, Krämer, Anna, Rödel, Claus, Eckert, Franziska, Paulsen, Frank, Kessel, Kerstin A., Combs, Stephanie E., Oehlke, Oliver, Grosu, Anca-Ligia, Seidlitz, Annekatrin, Lattermann, Annika, Krause, Mechthild, Baumann, Michael, and Guberina, Maja
- Subjects
- *
CANCER relapse , *COHORT analysis , *GLIOMAS , *CLINICAL trials , *PROGNOSIS , *DISEASE risk factors - Abstract
Background and purpose Reirradiation (reRT) is a valid option with considerable efficacy in patients with recurrent high-grade glioma, but it is still not known which patients might be optimal candidates for a second course of irradiation. This study validated a newly developed prognostic score independently in an external patient cohort. Material and methods The reRT risk score (RRRS) is based on a linear combination of initial histology, clinical performance status, and age derived from a multivariable model of 353 patients. This score can predict post-recurrence survival (PRS) after reRT. The validation dataset consisted of 212 patients. Results The RRRS differentiates three prognostic groups. Discrimination and calibration were maintained in the validation group. Median PRS times in the development cohort for the good/intermediate/poor risk categories were 14.2, 9.1, and 5.3 months, respectively. The respective groups within the validation cohort displayed median PRS times of 13.8, 8.8, and 3.8 months, respectively. Uno’s C for development data was 0.64 (CI: 0.60–0.69) and for validation data 0.63 (CI: 0.58–0.68). Conclusions The RRRS has been successfully validated in an independent patient cohort. This linear combination of three easily determined clinicopathological factors allows for a reliable classification of patients and may be used as stratification factor for future trials. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
200. Prognostic value of dynamic hypoxia PET in head and neck cancer: Results from a planned interim analysis of a randomized phase II hypoxia-image guided dose escalation trial.
- Author
-
Welz, Stefan, Mönnich, David, Pfannenberg, Christina, Nikolaou, Konstantin, Reimold, Mathias, La Fougère, Christian, Reischl, Gerald, Mauz, Paul-Stefan, Paulsen, Frank, Alber, Markus, Belka, Claus, Zips, Daniel, and Thorwarth, Daniela
- Subjects
- *
HYPOXEMIA , *HEAD & neck cancer treatment , *SQUAMOUS cell carcinoma , *CLINICAL trials , *PROGNOSIS , *MAMMALS - Abstract
Background and purpose To prospectively assess the prognostic value of tumour hypoxia determined by dynamic [ 18 F]Fluoromisonidazole (dynFMISO) PET/CT, and to evaluate both feasibility and toxicity in patients with locally advanced squamous cell carcinomas of the head and neck (LASCCHN) treated with dynFMISO image-guided dose escalation (DE) using dose-painting by contours. Patients and methods We present a planned interim analysis of a randomized phase II trial. N = 25 patients with LASCCHN received baseline dynFMISO PET/CT to derive hypoxic volumes (HV). Patients with tumour hypoxia were randomized into standard radiochemotherapy (stdRT) (70 Gy/35 fractions) or DE (77 Gy/35 fractions) to the HV. Patients with non-hypoxic tumours were treated with stdRT. Loco-regional control (LRC) in hypoxic patients randomized to stdRT was compared to non-hypoxic patients. Feasibility and toxicity were analysed for patients in the DE arm and compared to stdRT. Results With a mean follow-up of 27 months, LRC in hypoxic patients receiving stdRT ( n = 10) was significantly worse compared to the non-hypoxic group ( n = 5) (2y-LRC 44.4% versus 100%, p = 0.048). The respective LRC for the DE group ( n = 10) was 70.0%. Treatment compliance as well as acute and late toxicity did not show significant differences between the DE and the standard dose arms. Conclusion Tumour hypoxia determined by baseline dynFMISO PET/CT is associated with a high risk of local failure in patients with LASCCHN. First data suggest that DE to HV is feasible without excess toxicity. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.